{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:27:26Z","timestamp":1777307246109,"version":"3.51.4"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Pulm. circ."],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is characterized by progressive dyspnea and exercise limitation and is associated with reduced health\u2010related quality of life. Few clinical studies have evaluated the primary effects of treatment of PAH from the patient perspective. Here, we present the impact of riociguat on patient\u2010reported outcomes (PROs) in treatment\u2010na\u00efve patients with PAH. MOTION (NCT02191137) was an open\u2010label, phase 4 trial of riociguat monotherapy in treatment\u2010na\u00efve patients with PAH. The primary endpoint was the change in total score from baseline to Week 24\u00a0in the Living with Pulmonary Hypertension (LPH) questionnaire. The Short Form\u201012 Health Survey and Work Limitations Questionnaire 8 were also utilized to assess PROs. Other secondary endpoints included change from baseline in World Health Organization functional class (WHO FC), 6\u2010min walk distance (6MWD), Modified Borg Dyspnea Scale, and safety. At week 24 (n\u2009=\u200966), the mean (standard deviation [SD]) total LPH score was 37.17 (24.61), for a mean (SD) change from baseline of \u221210.99 (22.51). At last visit, with week 24 imputed, the mean (SD) total score was 40.63 (28.38), for a mean (SD) change from baseline of \u22125.40 (27.8) (n\u2009=\u200975; <jats:italic>P<\/jats:italic>\u2009=\u20090.0484). Improvement in LPH questionnaire total score was observed by week 4 and was maintained through week 24. Improvements were observed in WHO FC, Modified Borg Dyspnea Scale, and accelerometer\u2010measured 6MWD at week 24. Treatment with riociguat had a positive impact on PROs in treatment\u2010na\u00efve patients with PAH and was well tolerated, with a similar safety profile to that observed in placebo\u2010controlled phase 3 trials.<\/jats:p>","DOI":"10.1177\/2045894018823715","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T14:44:57Z","timestamp":1545403497000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Riociguat improves health\u2010related quality of life for patients with pulmonary arterial hypertension: results from the phase 4\u00a0MOTION study"],"prefix":"10.1002","volume":"9","author":[{"given":"Namita","family":"Sood","sequence":"first","affiliation":[{"name":"McGovern Medical School The University of Texas Health Science Center at Houston Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Aranda","sequence":"additional","affiliation":[{"name":"CardioPulmonary Research Center San Juan Puerto Rico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4625-0721","authenticated-orcid":false,"given":"David","family":"Platt","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals Inc. Whippany NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneliese","family":"LaRose","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals Inc. Whippany NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Kleinjung","sequence":"additional","affiliation":[{"name":"Bayer AG Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Bayer HealthCare Pharmaceuticals Inc. Whippany NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,2]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.01.004"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-6-92"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.034"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200802-020SK"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.1.92"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.04.007"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.026"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000273"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655"},{"key":"e_1_2_8_11_1","volume-title":"Adempas (riociguat) Prescribing Information","author":"Bayer HealthCare Pharmaceuticals, Inc","year":"2014"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00090614"},{"key":"e_1_2_8_13_1","unstructured":"Rubin LJ Galie N Grimminger F et al. Presented at: European Respiratory Society International Congress; Munich Germany; September 2014."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-161"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.11.002"},{"key":"e_1_2_8_17_1","unstructured":"Food and Drug Administration. The Voice of the Patient: Pulmonary Arterial Hypertension. Washington DC: U.S. FDA 2014. Available at:https:\/\/www.fda.gov\/downloads\/ForIndustry\/UserFees\/PrescriptionDrugUserFee\/UCM429382.pdf(accessed 5\u00a0July 2017)."},{"key":"e_1_2_8_18_1","unstructured":"Peacock A Galie N Barbera J et al. Initial Combination Therapy of Ambrisentan and Tadalafil and Quality of Life: SF\u201036 & CAMPHOR Analyses from the AMBITION Trial. Presented at: American Thoracic Society San Diego CA; May 18\u201323 2017. Poster A6905."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2008.11.011"}],"container-title":["Pulmonary Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2045894018823715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1177\/2045894018823715","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2045894018823715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T15:47:29Z","timestamp":1693237649000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1177\/2045894018823715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1177\/2045894018823715"],"URL":"https:\/\/doi.org\/10.1177\/2045894018823715","archive":["Portico"],"relation":{},"ISSN":["2045-8940","2045-8940"],"issn-type":[{"value":"2045-8940","type":"print"},{"value":"2045-8940","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}